Coronary Artery Stenosis Clinical Trial
— CHOICE-FROfficial title:
Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis
The purpose of the current study is to assess complete coronary physiology (FFR, RFR, CFR, IMR, and CT-FFR) in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI. This aims to determine how TAVI affects coronary blood flow and coronary microcirculatory function after longer-term follow-up, and how these effects influence FFR and RFR values. In addition, it is aimed to correlate invasive functional testing (FFR and RFR) with non-invasive CT-FFR before and 6 months after TAVI.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | June 30, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age >18 years - Willing to participate and able to understand, read and sign the informed consent document before the planned procedure - Severe symptomatic aortic stenosis with indication for TAVI according to current guidelines deemed by the Heart Team - Patients who have undergone coronary CT angiography before TAVI in which CAD could not be ruled out - CAD in one or more native major epicardial vessels or their branches by coronary angiogram with visually assessed coronary stenosis, in which the physiological severity of the lesion is in question (typically 40-90% diameter stenosis). - Eligible for invasive coronary angiography and functional assessment (FFR, RFR, CFR and IMR) - Eligible for coronary CT-angiography and functional assessment (CT-FFR) Exclusion Criteria: - Patients whose CT-angiography was determined to be non-diagnostic/unreadable during its evaluation - Previous coronary artery bypass grafting with patent grafts to the interrogated vessel - Patients with severe lesions with a diameter stenosis = 90%, flow-limiting lesions, or a significant left main coronary artery stenosis - Critical coronary artery disease deemed by the Heart Team to require immediate revascularization - Contraindication to adenosine (e.g. bronchial asthma) - Chronic renal impairment with severe reduction of glomerular filtration rate (eGFR <30 ml/min) - Presence of cardiogenic shock - Participation in another interventional study involving the left heart or coronary arteries |
Country | Name | City | State |
---|---|---|---|
Germany | Heart Center Leipzig at University of Leipzig Department of Internal Medicine/Cardiology | Leipzig |
Lead Sponsor | Collaborator |
---|---|
Helios Health Institute GmbH | Heart Center Leipzig - University Hospital |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of CFR, IMR, FFR and RFR values before TAVI and 6 months after TAVI | Comparison of coronary flow reserve, index of microvascular resistance, fractional flow reserve and resting full cycle ratio.
The variation in correlation between CT-FFR and IMR, FFR or RFR before and after TAVI will be estimated using a General Linear Model (GLM) with an interaction between the independent variable (IMR, FFR, RFR) and the time period (before or after TAVI). |
6 Months | |
Secondary | Diagnostic accuracy by considering FFR values of >0.80 as normal | diagnostic accuracy (sensitivity, specificity, positive predictive value [PPV] and negative predictive value [NPV]) of CT-FFR for the detection of significant coronary stenosis before and 6 months after TAVI by considering FFR values of >0.80 as normal | 6 Months | |
Secondary | Diagnostic accuracy by considering RFR values of >0.89 as normal | diagnostic accuracy (sensitivity, specificity, positive predictive value [PPV] and negative predictive value [NPV]) of CT-FFR for the detection of significant coronary stenosis before and 6 months after TAVI by considering RFR values of >0.89 as normal | 6 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
Completed |
NCT01332591 -
Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy.
|
N/A | |
Completed |
NCT01182428 -
XIENCE V: SPIRIT WOMEN Sub-study
|
Phase 4 | |
Completed |
NCT00739466 -
Biorest Liposomal Alendronate With Stenting sTudy (BLAST)
|
Phase 2 | |
Completed |
NCT00531011 -
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
|
Phase 4 | |
Completed |
NCT01310309 -
EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease
|
Phase 4 | |
Not yet recruiting |
NCT06052670 -
Functional Diagnostic Accuracy of Ultrasonic Flow Ratio in Assessment of Coronary Artery Lesions
|
||
Completed |
NCT05509296 -
Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
|
N/A | |
Not yet recruiting |
NCT05393882 -
Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
|
||
Recruiting |
NCT06397820 -
Relation Between AI-QCA and Cardiac PET
|
||
Active, not recruiting |
NCT01960504 -
First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)
|
N/A | |
Completed |
NCT01721096 -
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
|
||
Active, not recruiting |
NCT01342822 -
Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization
|
Phase 4 | |
Completed |
NCT01205789 -
EXCEL Clinical Trial (Universal Registry)
|
N/A | |
Recruiting |
NCT05532605 -
Effects of Mindfulness Based Therapy on Illness and Depression in Cardiac Rehab Phase-i
|
N/A | |
Completed |
NCT02066623 -
Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold
|
||
Not yet recruiting |
NCT02946320 -
Optimal Predilatation Technique for BVS Implantation
|
Phase 3 | |
Completed |
NCT01136876 -
Kidney Damage in Patients With Moderate Fall in eGFR
|
Phase 4 | |
Terminated |
NCT01136915 -
Kidney Damage In Patients With Severe Fall In eGFR
|
Phase 4 | |
Completed |
NCT01249027 -
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
|